Based on the ProQR Therapeutics BV stock forecast from 7 analysts, the average analyst target price for ProQR Therapeutics BV is USD 9.11 over the next 12 months. ProQR Therapeutics BV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ProQR Therapeutics BV is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, ProQR Therapeutics BV’s stock price was USD 1.20. ProQR Therapeutics BV’s stock price has changed by -12.41% over the past week, -37.17% over the past month and -46.90% over the last year.
No recent analyst target price found for ProQR Therapeutics BV
No recent average analyst rating found for ProQR Therapeutics BV
Company Overview ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Read Less
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardio...Read More
Frequently Asked Questions About ProQR Therapeutics BV (PRQR) Stock
Based on ratings from 7 analysts ProQR Therapeutics BV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 9 buy, sell and hold ratings.
Unfortunately we do not have enough data on PRQR's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for PRQR is USD 9.11 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on PRQR's stock to indicate if its overvalued.
The last closing price of PRQR's stock was USD 1.20.
The most recent market capitalization for PRQR is USD 0.17B.
Based on targets from 7 analysts, the average taret price for PRQR is projected at USD 9.11 over the next 12 months.
This means that PRQR's stock price may go up by +659.26% over the next 12 months.
We can't find any ETFs which contains ProQR Therapeutics BV's stock.
As per our most recent records ProQR Therapeutics BV has 166 Employees.
ProQR Therapeutics BV's registered address is Zernikedreef 9, Leiden, Netherlands, 2333 CK.
You can get more information about it from ProQR Therapeutics BV's website at https://www.proqr.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About ProQR Therapeutics BV (PRQR) Stock
Based on ratings from 7 analysts ProQR Therapeutics BV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 9 buy, sell and hold ratings.
Unfortunately we do not have enough data on PRQR's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for PRQR is USD 9.11 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on PRQR's stock to indicate if its overvalued.
The last closing price of PRQR's stock was USD 1.20.
The most recent market capitalization for PRQR is USD 0.17B.
Based on targets from 7 analysts, the average taret price for PRQR is projected at USD 9.11 over the next 12 months.
This means that PRQR's stock price may go up by +659.26% over the next 12 months.
We can't find any ETFs which contains ProQR Therapeutics BV's stock.
As per our most recent records ProQR Therapeutics BV has 166 Employees.
ProQR Therapeutics BV's registered address is Zernikedreef 9, Leiden, Netherlands, 2333 CK.
You can get more information about it from ProQR Therapeutics BV's website at https://www.proqr.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRQR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
